250 related articles for article (PubMed ID: 21506957)
1. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
Gesty-Palmer D; Luttrell LM
Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
[TBL] [Abstract][Full Text] [Related]
2. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
Bohinc BN; Gesty-Palmer D
Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
[TBL] [Abstract][Full Text] [Related]
3. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
Bohinc BN; Gesty-Palmer D
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
[TBL] [Abstract][Full Text] [Related]
4. Arrestins in bone.
Bohinc BN; Gesty-Palmer D
Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
[TBL] [Abstract][Full Text] [Related]
5. Translating in vitro ligand bias into in vivo efficacy.
Luttrell LM; Maudsley S; Gesty-Palmer D
Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
[TBL] [Abstract][Full Text] [Related]
6. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
[TBL] [Abstract][Full Text] [Related]
7. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
[TBL] [Abstract][Full Text] [Related]
8. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.
Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM
Sci Transl Med; 2009 Oct; 1(1):1ra1. PubMed ID: 20368153
[TBL] [Abstract][Full Text] [Related]
9. Refining efficacy: exploiting functional selectivity for drug discovery.
Gesty-Palmer D; Luttrell LM
Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
[TBL] [Abstract][Full Text] [Related]
10. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
[TBL] [Abstract][Full Text] [Related]
11. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
12. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone.
Goltzman D
Arch Biochem Biophys; 2008 May; 473(2):218-24. PubMed ID: 18358824
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
Cupp ME; Nayak SK; Adem AS; Thomsen WJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
[TBL] [Abstract][Full Text] [Related]
15. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
Esbrit P; Alcaraz MJ
Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
[TBL] [Abstract][Full Text] [Related]
17. Emergent biological properties of arrestin pathway-selective biased agonism.
Appleton KM; Luttrell LM
J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
[TBL] [Abstract][Full Text] [Related]
18. Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.
Hanyu R; Wehbi VL; Hayata T; Moriya S; Feinstein TN; Ezura Y; Nagao M; Saita Y; Hemmi H; Notomi T; Nakamoto T; Schipani E; Takeda S; Kaneko K; Kurosawa H; Karsenty G; Kronenberg HM; Vilardaga JP; Noda M
Proc Natl Acad Sci U S A; 2012 May; 109(19):7433-8. PubMed ID: 22538810
[TBL] [Abstract][Full Text] [Related]
19. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone.
Yang D; Singh R; Divieti P; Guo J; Bouxsein ML; Bringhurst FR
Bone; 2007 Jun; 40(6):1453-61. PubMed ID: 17376756
[TBL] [Abstract][Full Text] [Related]
20. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
Tay D; Cremers S; Bilezikian JP
Br J Clin Pharmacol; 2018 Feb; 84(2):252-267. PubMed ID: 29049872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
